Search global stocks & ETFs...Ctrl K
Learn Mode
INSM
Stock Profile
08-05
Recommended Metric
Score Card
Explore Scores Tab
3.11
Average
Valuation Score
Key Score
3.00
Average
Management
1.00
Very Bad
Growth
2.00
Bad
Profitability
3.00
Average
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$111.60
Baseline
High
$255.15
▲
128.63%
Avg
$209.02
▲
87.30%
Low
$141.40
▲
26.70%
Analyst Ratings based on 29 Analysts
Strong Buy
931%
Buy
1966%
Hold
103%
Sell
000%
Strong Sell
000%
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,664 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.Read More